A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study

Blood
Harry R BullerEinstein-DVT Dose-Ranging Study investigators

Abstract

We performed a randomized dose-ranging study, double-blind for rivaroxaban doses and open-label for the comparator (low-molecular-weight heparin followed by vitamin K antagonists) to assess the optimal dose of rivaroxaban for the treatment of deep vein thrombosis. A total of 543 patients with acute deep-venous thrombosis received rivaroxaban 20, 30, or 40 mg once daily or comparator. Treatment lasted for 84 days. The primary efficacy outcome was the 3-month incidence of the composite of symptomatic venous thromboembolic complications and asymptomatic deterioration in thrombotic burden as assessed by comparison of ultrasound and perfusion lung scanning at day 84 with baseline. The main safety outcome was the composite of major bleeding and clinically relevant nonmajor bleeding. A total of 449 (83%) of the 543 patients could be included in the per-protocol population. The primary efficacy outcome occurred in 6.1%, 5.4%, and 6.6% of the rivaroxaban 20-, 30-, and 40-mg treatment groups, respectively, and in 9.9% of those receiving standard therapy. The main safety outcome occurred in 5.9%, 6.0%, and 2.2% of the rivaroxaban 20-, 30-, and 40-mg treatment groups, respectively, and in 8.8% of those receiving standard therapy. These res...Continue Reading

References

May 1, 1978·British Journal of Haematology·T L SimonL A Harker
Apr 1, 1976·Circulation·J HirshW L Yung
Feb 16, 1999·Lancet·A W LensingH R Büller
Oct 31, 2003·The New England Journal of Medicine·H R BüllerUNKNOWN Matisse Investigators
Jun 3, 2004·Annals of Internal Medicine·Harry R BüllerUNKNOWN Matisse Investigators
Aug 9, 2005·European Journal of Internal Medicine·Yshai Y YavinAlexander T Cohen
Aug 17, 2005·Journal of Thrombosis and Haemostasis : JTH·J I Weitz, S M Bates
Oct 4, 2005·Clinical Pharmacology and Therapeutics·Dagmar KubitzaGeorg Wensing
Sep 15, 2007·The New England Journal of Medicine·UNKNOWN van Gogh InvestigatorsGary E Raskob
Jun 27, 2008·The New England Journal of Medicine·Bengt I ErikssonUNKNOWN RECORD1 Study Group
Jun 27, 2008·The New England Journal of Medicine·Michael R LassenUNKNOWN RECORD3 Investigators

❮ Previous
Next ❯

Citations

Mar 24, 2012·Zeitschrift für Gerontologie und Geriatrie·R E Roller, P Feichtinger
May 15, 2013·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·T SteinerR Veltkamp
Oct 20, 2009·Journal of Thrombosis and Thrombolysis·Meyer Michel Samama, Grigoris T Gerotziafas
Dec 17, 2009·Journal of General Internal Medicine·Gerald W Smetana, Jane S Sillman
Jun 29, 2013·Advances in Therapy·Thomas Vanassche, Peter Verhamme
Aug 21, 2013·Best Practice & Research. Clinical Haematology·Giancarlo AgnelliLaura Franco
Dec 18, 2010·Nature Reviews. Drug Discovery·Elisabeth PerzbornFrank Misselwitz
Dec 7, 2010·The New England Journal of Medicine·Rupert BauersachsSebastian Schellong
Mar 28, 2012·The New England Journal of Medicine·Harry R BüllerAnnelise Segers
May 13, 2010·American Journal of Therapeutics·Dhara ChaudhariRohit Arora
Jun 11, 2010·American Journal of Therapeutics·Maryam Sattari, David T Lowenthal
Jun 25, 2009·Current Opinion in Hematology·Jennifer Carreiro Zikria, Jack Ansell
Feb 19, 2009·International Journal of Clinical Practice·C W KhooG Y H Lip
Jun 30, 2010·International Journal of Clinical Practice·J M Walenga, C Adiguzel
Jan 14, 2011·Annual Review of Medicine·Bengt I ErikssonJohn W Eikelboom
Jul 20, 2013·International Journal of Emergency Medicine·Patrick GoldsteinEric Wiel
Aug 13, 2010·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Noriko KonishiMasaki Kawamura
Jun 9, 2009·Clinical Interventions in Aging·Helia Robert-EbadiMarc Righini
Aug 27, 2009·Vascular Health and Risk Management·Andrew D Blann, Chee W Khoo
Oct 23, 2010·Drugs·Hans-Juergen Rupprecht, Ralf Blank
Jun 30, 2009·Journal of Cardiovascular Medicine·Jan Steffel, Thomas F Lüscher
Jun 21, 2011·Hämostaseologie·M LeviP W Kampuisen
Jul 11, 2012·Hämostaseologie·T HelbingM Moser
Mar 22, 2014·Current Opinion in Rheumatology·Savino SciasciaDavid P D'Cruz
Jul 23, 2013·Vascular Pharmacology·Giulia Renda, Raffaele De Caterina
Jan 24, 2014·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Yishen Wang, Beata Bajorek
Dec 3, 2013·Journal of Thrombosis and Thrombolysis·Reinhold Kreutz
Nov 22, 2011·Revue des maladies respiratoires·L Bertoletti, P Mismetti
May 30, 2014·Internal and Emergency Medicine·Paolo PrandoniAlì Taher
Aug 30, 2014·Clinics in Laboratory Medicine·Meyer Michel SamamaCharles Marc Samama
May 12, 2012·Wiener klinische Wochenschrift·Gisela ScharbertSibylle Kozek-Langenecker
Sep 1, 2009·Clinical Drug Investigation·Parham Khosravi-Shahi, Gumersindo Pérez-Manga
Oct 5, 2010·European Journal of Anaesthesiology·Wiebke GogartenUNKNOWN European Scoeity of Anaesthesiology

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.